Cyclo Therapeutics Inc. (NASDAQ: CYTH) is 19.77% higher on its value in year-to-date trading and has touched a low of $3.40 and a high of $33.50 in the current 52-week trading range. The CYTH stock was last observed hovering at around $4.25 in the last trading session, with the day’s gains setting it 0.96% off its average median price target of $12.00 for the next 12 months. It is also 56.58% off the consensus price target high of $12.00 offered by 1 analysts, but current levels are 56.58% higher than the price target low of $12.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $5.21, the stock is 3.63% and -36.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 18.37 million and changing 22.59% at the moment leaves the stock -62.18% off its SMA200. CYTH registered -84.45% loss for a year compared to 6-month loss of -61.15%. The firm has a 50-day simple moving average (SMA 50) of $6.19 and a 200-day simple moving average (SMA200) of $11.89.
The stock witnessed a -30.53% gain in the last 1 month and extending the period to 3 months gives it a -60.26%, and is 11.56% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.49% over the week and 19.64% over the month.
Cyclo Therapeutics Inc. (CYTH) has around 8 employees, a market worth around $24.33M and $1.00M in sales. Distance from 52-week low is 53.24% and -84.45% from its 52-week high. The company has generated returns on investments over the last 12 months (-838.30%).
Cyclo Therapeutics Inc. (CYTH) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Cyclo Therapeutics Inc. (CYTH) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Cyclo Therapeutics Inc. is expected to release its quarterly report on 05/19/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to shrink by -33.80% this year, but quarterly earnings will post 0.30% year-over-year.
Cyclo Therapeutics Inc. (CYTH) Top Institutional Holders
4 institutions hold shares in Cyclo Therapeutics Inc. (CYTH), with 174.01k shares held by insiders accounting for 10.24% while institutional investors hold 0.07% of the company’s shares. The shares outstanding are 151.95M, and float is at 4.45M with Short Float at 0.11%. Institutions hold 0.06% of the Float.
The top institutional shareholder in the company is Wendell (David) Associates, Inc. with over 300.0 shares valued at $4200.0. The investor’s holdings represent 0.01% of the CYTH Shares outstanding.